STEMTARGET

Targeting Leukemia Stem Cells

 Coordinatore LUNDS UNIVERSITET 

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Mrs
Nome: Anette
Cognome: Welin
Email: send email
Telefono: +4646222 82 72

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-CIG
 Funding Scheme MC-CIG
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-03-01   -   2018-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Mrs
Nome: Anette
Cognome: Welin
Email: send email
Telefono: +4646222 82 72

SE (LUND) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

aring    identification    shrna    screen    selectively    mice    leukemic    stemtarget    proof    leukemia       surface    screens    lsc    vivo    cells    cell    cytokine    directed    therapeutic    stem    dr    lscs    auml    antibodies    coworkers   

 Obiettivo del progetto (Objective)

'Targeting Leukemia Stem Cells

The major goals of STEMTARGET is to identify novel targets on leukemic stem cells (LSCs), generate novel insights into LSC biology, and to initiate the development of LSC-directed therapeutic antibodies. The research will focus on three specific aims: (I) To characterize novel cell surface targets on LSCs, identified by in vivo RNA interference screens. (II) To utilize an in-house developed cytokine screen for identification of cell surface targets selectively important for LSCs. (III) To measure receptor expression in patient samples and demonstrate proof of concept for therapeutic effect with antibody-treatment of leukemic mice.

Background: In adults, AML has a poor prognosis, and novel therapies are needed. In order to be maximally effective, an important goal for the development of novel treatments is to target all leukemia cells with the ability to self renew and maintain the disease indefinitely, a population termed LSCs. During Dr Järås postdoctoral training at Harvard Medical School, Boston, he and coworkers developed a potent in vivo shRNA screen and used it to identify therapeutic targets in LSCs, towards both small molecules and blocking antibodies could be directed. In addition, Dr Järås has developed a cytokine screen for identification of cell surface targets selectively important for LSCs.

In STEMTARGET, Dr Järås and coworkers will perform further shRNA screens and cytokine screens for the identification and characterization of candidate therapeutic targets on LSCs. Monoclonal antibodies targeting identified cell surface targets will be generated and proof of concept experiments for therapeutic targeting will be performed by treating mice with established leukemia. Successful completion of this research program will identify novel targets on LSC, and provide initial validation of therapeutic potential.'

Altri progetti dello stesso programma (FP7-PEOPLE)

WW1 ALLIED CULTURES (2011)

Inter-Allied Cultures and Identities during World War 1

Read More  

HOSPITABLE EUROPE (2012)

Hospitality vs Hatred of the Other: A Study of Welcoming versus Prejudiced Representations of Otherness in Britain and Poland

Read More  

RISKEQCC (2010)

Risk and Equity in Climate Change Problems

Read More